Form 4: Dianthus Therapeutics EVP Sells Shares Post-Option Exercise

Dianthus Therapeutics EVP and Head of R&D, Simrat Randhawa, executed pre-planned sales of common stock following option exercises.

Summary

• Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics, Inc. (DNTH), reported transactions involving the company's common stock.
• On November 13, 2025, Randhawa exercised stock options to acquire 83,978 shares at $8.44 per share and 3,529 shares at $17.88 per share.
• On the same day, Randhawa sold a total of 87,507 shares (26,166 shares at a weighted average price of $35.80, 42,765 shares at $37.04, and 18,576 shares at $37.72).
• On November 14, 2025, Randhawa exercised additional stock options to acquire 40,287 shares at $17.88, 37,494 shares at $21.77, and 31,250 shares at $22.07.
• Also on November 14, 2025, Randhawa sold 109,031 shares at a weighted average price of $38.14.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.
• Following these transactions, Randhawa beneficially owns 4,000 shares of Dianthus Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While executive selling can sometimes be a negative signal, the fact that these transactions were pre-planned under a Rule 10b5-1 plan mitigates concerns about insider information. The executive also realized a significant gain from option exercises, which is a positive for personal wealth but not necessarily a strong signal for the company's future stock performance.

Positives

• The executive exercised stock options, indicating a belief in the value of the company's stock at the time of vesting and exercise.
• The sale prices for the common stock were significantly higher than the exercise prices of the options, resulting in a substantial personal gain for the executive.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the sales were not based on new, non-public information.

Negatives

• A significant reduction in the executive's direct beneficial ownership of common stock (from 87,978 shares to 4,000 shares after the first day's transactions, and maintaining 4,000 shares after the second day's transactions) could be perceived negatively by some investors.
• Executive sales, even if pre-planned, can sometimes lead to questions about management's long-term conviction in the company's stock.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction; it solely reports insider transactions.

Management Comments

• The transactions were executed under a Rule 10b5-1 trading plan adopted on August 14, 2025.

Industry Context

Insider transaction reports (Form 4s) are routine disclosures for publicly traded companies, providing transparency into executive stock ownership and trading activities. Such pre-planned sales under Rule 10b5-1 are common for executives managing their personal finances and diversifying their portfolios, especially when compensation includes significant equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe the executive's reduced direct ownership, but the pre-planned nature of the sales under a 10b5-1 plan should alleviate concerns about opportunistic selling.
• Employees: No direct impact mentioned, but executive compensation practices are generally transparent.

Next Steps

• Continued vesting of remaining stock option awards as per their respective schedules, subject to the Reporting Person's continued service to the Issuer.

Key Dates

Recommendation

The reported transactions are routine insider sales executed under a pre-arranged Rule 10b5-1 trading plan, which mitigates the typical negative signal of executive selling. The executive exercised options and sold shares, likely for diversification or liquidity purposes, rather than based on new material non-public information. This type of transaction does not provide a strong signal for a 'buy' or 'sell' recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Dianthus Therapeutics, DNTH, Insider Trading, Form 4, Stock Sale, Option Exercise, Simrat Randhawa, Executive Compensation, Rule 10b5-1